Spring­Works gets pri­or­i­ty re­view; Botox com­peti­tor da­ta; Hyundai's Covid treat­ment; Ar­cus takes a loan

Spring­Works scores FDA pri­or­i­ty re­view: The agency ac­cept­ed mir­dame­tinib’s new drug ap­pli­ca­tion and grant­ed it a pri­or­i­ty re­view for the treat­ment of adult and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER